Summary:
In adults with obesity-related heart failure with preserved ejection fraction (HFpEF), left ventricular ejection fraction ≥45%, and BMI ≥30 kg/m², weekly semaglutide 2.4 mg for 52 weeks significantly improved HFpEF symptoms, physical limitations, and exercise capacity, with weight loss more pronounced in women (-9.6%) than men (-7.2%) compared to matched placebo with standard care, though it was associated with fewer serious adverse events than placebo.
| PICO | Description |
|---|---|
| Population | Adults with obesity-related heart failure with preserved ejection fraction (HFpEF), left ventricular ejection fraction ≥45%, and body mass index (BMI) ≥30 kg/m², including both male and female participants, assessed for sex-specific differences in baseline characteristics and treatment outcomes. |
| Intervention | Weekly administration of semaglutide 2.4 mg for 52 weeks to improve HF-related symptoms, physical limitations, exercise capacity, and reduce body weight. |
| Comparison | Matched placebo used once weekly alongside usual standard of care for patients with obesity-related HFpEF over a 52-week period. |
| Outcome | Semaglutide significantly improved HFpEF symptoms (mean KCCQ-CSS improvement of +7.6 points for women and +7.5 points for men), physical limitations, and exercise capacity in both sexes. It reduced body weight more in women (-9.6%) compared to men (-7.2%), with fewer serious adverse events reported in the semaglutide group compared to the placebo group. |
Source: Subodh Verma, et al. “Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials.” Journal of the American College of Cardiology, 2024 Aug 27; 84(9):773-785. Read article here.
